212 related articles for article (PubMed ID: 26700310)
1. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
Wu W; Ma D; Wang P; Cao L; Lu T; Fang Q; Zhao J; Wang J
FEBS J; 2016 Mar; 283(5):834-49. PubMed ID: 26700310
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes multiple myeloma resistance through the JAK2/STAT3 pathway.
Huang J; Huang LQ; He HS; Yan J; Huang C; Wang R; Guan Y; Huang DP
Life Sci; 2020 Sep; 257():118088. PubMed ID: 32663573
[TBL] [Abstract][Full Text] [Related]
3. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Tang S; Ma D; Cheng B; Fang Q; Kuang X; Yu K; Wang W; Hu B; Wang J
Exp Cell Res; 2018 Feb; 363(2):196-207. PubMed ID: 29317217
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
[TBL] [Abstract][Full Text] [Related]
5. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.
Zhang Z; Wang W; Ma D; Xiong J; Kuang X; Zhang S; Fang Q; Wang J
Aging (Albany NY); 2020 Apr; 12(8):6611-6629. PubMed ID: 32298237
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
Alas S; Bonavida B
Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
Barrera LN; Rushworth SA; Bowles KM; MacEwan DJ
Cell Cycle; 2012 Jun; 11(12):2248-52. PubMed ID: 22617388
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.
Kawano Y; Fujiwara S; Wada N; Izaki M; Yuki H; Okuno Y; Iyama K; Yamasaki H; Sakai A; Mitsuya H; Hata H
Int J Oncol; 2012 Sep; 41(3):876-84. PubMed ID: 22766978
[TBL] [Abstract][Full Text] [Related]
11. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
12. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
[TBL] [Abstract][Full Text] [Related]
13. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
[TBL] [Abstract][Full Text] [Related]
14. As
Wu D; Dong W; Fang K; Wang M
Technol Cancer Res Treat; 2019; 18():1533033819896806. PubMed ID: 31868118
[TBL] [Abstract][Full Text] [Related]
15. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy.
Tan Q; Wang H; Hu Y; Hu M; Li X; Aodengqimuge ; Ma Y; Wei C; Song L
Cancer Sci; 2015 Aug; 106(8):1023-32. PubMed ID: 26041409
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
18. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Liu Y; Liu A; Li H; Li C; Lin J
Cancer Prev Res (Phila); 2011 Aug; 4(8):1296-305. PubMed ID: 21490132
[TBL] [Abstract][Full Text] [Related]
19. cAMP/PKA enhances interleukin-1β-induced interleukin-6 synthesis through STAT3 in glial cells.
Tanabe K; Kozawa O; Iida H
Cell Signal; 2016 Jan; 28(1):19-24. PubMed ID: 26527061
[TBL] [Abstract][Full Text] [Related]
20. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells.
Pedranzini L; Dechow T; Berishaj M; Comenzo R; Zhou P; Azare J; Bornmann W; Bromberg J
Cancer Res; 2006 Oct; 66(19):9714-21. PubMed ID: 17018630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
